A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2014
At a glance
- Drugs Sapacitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Cyclacel Pharmaceuticals
- 07 Feb 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Dec 2011 Interim results reported in a Cyclacel media release.
- 07 Nov 2011 Planned End Date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.